The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications
- Gemma TremoladaAffiliated withDepartment of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute
- , Rosangela LattanzioAffiliated withDepartment of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute
- , Gabriella MazzolariAffiliated withRenal Pathophysiology Unit, San Raffaele Scientific Institute
- , Gianpaolo ZerbiniAffiliated withRenal Pathophysiology Unit, San Raffaele Scientific InstituteDivision of Medicine, San Raffaele Scientific Institute Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus.
The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin).
According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.
- The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications
American Journal of Cardiovascular Drugs
Volume 7, Issue 6 , pp 393-398
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute, Milan, Italy
- 2. Renal Pathophysiology Unit, San Raffaele Scientific Institute, Milan, Italy
- 3. Division of Medicine, San Raffaele Scientific Institute, Via Olgettina, Milan, 60 I — 20132, Italy